February 2018

New Indications

Gazyva (obinutuzumab (rch)) in combination with chemotherapy followed by Gazyva maintenance is now indicated for the treatment of previously untreated advanced follicular lymphoma.

Xalkori (crizotinib) is now indicated for the treatment of ROS1 positive advanced non-small cell lung cancer.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au